Membranous nephropathy (MN) is a unique glomerular lesion that is the most common
cause of idiopathic nephrotic syndrome in nondiabetic white adults. About 80% of cases are …

Recent work has provided new insights into how altered B cell-intrinsic signals—through the
B cell receptor (BCR) and key co-receptors—function together to promote the pathogenesis …

Glomerular disease, be it primary or secondary, occurring in the setting of systemic
autoimmune diseases, infections, drugs, or malignancy, affects individuals of all ages. In …

Background B-cell anomalies play a role in the pathogenesis of membranous nephropathy.
B-cell depletion with rituximab may therefore be noninferior to treatment with cyclosporine …

Background A cyclic corticosteroid-cyclophosphamide regimen is the first-line therapy for
membranous nephropathy. Compared with this regimen, rituximab therapy might have a …

The Kidney Disease: Improving Global Outcomes (KDIGO) initiative organized a
Controversies Conference on glomerular diseases in November 2017. The conference …

Introduction Narsoplimab is a human monoclonal antibody against mannan-associated
lectin-binding serine protease− 2 (MASP-2). Now in a phase 3 study, narsoplimab was …

Membranous nephropathy (MN) is a glomerular disease that can occur at all ages. In adults,
it is the most frequent cause of nephrotic syndrome. In~ 80% of patients, there is no …

A cyclical corticosteroid-cyclophosphamide regimen is recommended for patients with
primary membranous nephropathy at high risk of progression. We hypothesized that …

Background: During the past years biologic agents (also termed biologicals or biologics)
have become a crucial treatment option in immunological diseases. Numerous articles have …